Vor Biopharma (VOR) Stock Price, News & Analysis

Company Overview

Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.

Key Stats

• Today's Range: $14.17 to $14.78
• 50-Day Range: $12.04 to $18.05
• 52-Week Range: $3.63 to $65.80
• Volume: 533,238 shs
• Average Volume: 824,673 shs
• Market Capitalization: $789.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.25
• Consensus Rating: Moderate Buy

Vor Biopharma Stock Analysis - MarketRank™

Vor Biopharma scored higher than 56% of companies evaluated by MarketBeat, and ranked 42nd out of 86 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vor Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 2 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Vor Biopharma has a consensus price target of $42.25, representing about 190.0% upside from its current price of $14.57.

Amount of Analyst Coverage

Vor Biopharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vor Biopharma are expected to decrease in the coming year, from ($2.51) to ($3.40) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.52% of the float of Vor Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Vor Biopharma has a short interest ratio ("days to cover") of 5.26.

Change versus previous month

Short interest in Vor Biopharma has recently decreased by 7.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vor Biopharma does not currently pay a dividend.

Dividend Growth

Vor Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.62

News Sentiment

Vor Biopharma has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Vor Biopharma this week, compared to 5 articles on an average week.

Search Interest

Only 8 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,412,176.00 in company stock.

Percentage Held by Insiders

0.45% of the stock of Vor Biopharma is held by insiders.

Percentage Held by Institutions

97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/30/2026
• Today: 6/01/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Biological Products, Except Diagnostic Substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VOR
• Previous Symbol: NASDAQ:VOR
• CIK: 1817229
• Web: N/A
• Phone: (617) 655-6580
• Fax: N/A
• Employees: 140
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Vor Biopharma: $42.25
• High Price Target: $64.00
• Low Price Target: $18.00
• Potential Upside/Downside: +190.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,186,000
• Free Float: 54,040,000
• Market Cap: $789.49 million
• Optionable: N/A
• Beta: 1.75